News
-
-
-
-
PRESS RELEASE
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
NanoViricides, Inc. reports NV-387 antiviral drug could reduce metastatic cancer resurgence caused by viral infections. NV-387 completed Phase I trial, advancing to Phase II -
-
PRESS RELEASE
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
NanoViricides introduces drug candidate NV-387 as a potential treatment for Measles outbreak. The drug has shown safety and effectiveness in animal studies and Phase I trial, aiming to combat the global epidemic -
-
PRESS RELEASE
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
NanoViricides, Inc. highlights the strong effectiveness of its broad-spectrum antiviral drug NV-387 against various viruses. Expected to drive significant valuation and market share, leading to rapid regulatory approvals and early revenues -
-
PRESS RELEASE
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
NanoViricides, Inc., a leading global pioneer in broad-spectrum antivirals, achieves significant success in developing a drug against Measles with NV-387. The drug shows strong antiviral effectiveness in recent studies
